Skip to content
Open in App
Abivax logo

Abivax

web2

ABIVAX Société Anonyme, a clinical-stage biotechnology company, develops therapeutics that harn...

Symbol · ABVX
Company profile

About

ABIVAX Société Anonyme, a clinical-stage biotechnology company, develops therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Its lead drug candidate includes obefazimod, which is in Phase 3 clinical development for the treatment of moderately to severely active UC, as well as Phase 2b clinical trials for Crohn’s disease. The company was incorporated in 2013 and is headquartered in Paris, France.

Explore by sector

Explore this sector

Market identity

Exchange listings

Listing identities only. Orbitrum does not publish live prices or market performance on this public profile.

ExchangeNasdaqPrimary symbol: ABVX
ExchangeFrankfurtPrimary symbol: ABVX
ExchangeViennaPrimary symbol: ABVX
ExchangeParisPrimary symbol: ABVX
Expert coverage

1 expert evaluated Abivax.

Orbitrum research

Experts evaluating Abivax

Explore the public profiles of experts who have evaluated this project.

Orbitrum Academy

Learn how to read a project assessment